Send to

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2015 Jul 15;212(2):258-63. doi: 10.1093/infdis/jiv022. Epub 2015 Jan 13.

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

Author information

  • 1Department of Medicine.
  • 2Department of Molecular Virology and Microbiology, Department of Immunology, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas.
  • 3Department of Cellular Therapy, Children's National Medical Center, Washington, District of Columbia.
  • 4Department of Medicine Department of Microbiology and Immunology Department of Epidemiology, University of North Carolina Chapel Hill, Chapel Hill.


Enhanced human immunodeficiency virus (HIV)-specific immunity may be required for HIV eradication. Administration of autologous, ex vivo expanded, virus-specific, cytotoxic T-lymphocytes derived from HIV-infected patients on suppressive antiretroviral therapy (HXTCs) are a powerful tool for proof-of-concept studies. Broadly specific, polyclonal HXTCs resulting from ex vivo expansion demonstrated improved control of autologous reservoir virus compared to bulk CD8(+) T cells in viral inhibition assays. Furthermore, patient-derived HXTCs were able to clear latently infected autologous resting CD4(+) T cells following exposure to the latency-reversing agent, vorinostat. HXTCs will be ideal reagents to administer with precise control in future in vivo studies in combination with latency-reversing agents.


HIV T cells; HIV cure; HIV eradication; HIV immunology; adoptive T-cell therapy; ex vivo expanded T cells; latent reservoir; vorinostat

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center